Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for G1 Therapeutics (GTHX : NSDQ)

• Company Description    G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel, small-molecule therapies which address significant unmet needs in the treatment of cancer. The company's product pipeline consists of CDK4/6, Trilaciclib (G1T28), G1T38 and G1T48. G1 Therapeutics, Inc. is based in Research Triangle Park, NC. Number of Employees: 148

• Price / Volume Information    Yesterday's Closing Price: $5.27 Daily Weekly Monthly 20 Day Moving Average: 1,021,819 shares Shares Outstanding: 42.71 (millions) Market Capitalization: $225.06 (millions) Beta: 2.03 52 Week High: $24.12 52 Week Low: $4.25 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -20.27% -10.20% 12 Week -51.92% -47.13% Year To Date -48.38% -36.93%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 700 Park Offices Drive Suite 200 - Research Triangle Park,NC 27709 USA ph: 919-213-9835 fax: 919-741-5830 jmacdonald@g1therapeutics.com http://www.g1therapeutics.com

• General Corporate Information    Officers John E. Bailey, Jr. - President; Chief Executive Officer and Director Jennifer K. Moses - Chief Financial Officer Willie A. Deese - Director Glenn P. Muir - Director Garry A. Nicholson - Director Peer Information G1 Therapeutics (CORR.) G1 Therapeutics (RSPI) G1 Therapeutics (CGXP) G1 Therapeutics (BGEN) G1 Therapeutics (GTBP) G1 Therapeutics (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 3621LQ109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/03/22 Share - Related Items Shares Outstanding: 42.71 Most Recent Split Date: (:1) Beta: 2.03 Market Capitalization: $225.06 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.04 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.86 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/03/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.25 Price/Cash Flow: - Price / Sales: 9.32 EPS Growth vs. Year Ago Period: -76.92% vs. Previous Quarter: -22.34% Sales Growth vs. Year Ago Period: -51.46% vs. Previous Quarter: 19.08% ROE 03/31/22 - -107.75 12/31/21 - -76.03 09/30/21 - -65.66 ROA 03/31/22 - -68.95 12/31/21 - -54.80 09/30/21 - -50.57 Current Ratio 03/31/22 - 5.96 12/31/21 - 8.82 09/30/21 - 8.68 Quick Ratio 03/31/22 - 5.73 12/31/21 - 8.69 09/30/21 - 8.63 Operating Margin 03/31/22 - -708.20 12/31/21 - -471.32 09/30/21 - -316.58 Net Margin 03/31/22 - -708.20 12/31/21 - -471.32 09/30/21 - -316.58 Pre-Tax Margin 03/31/22 - -704.95 12/31/21 - -468.38 09/30/21 - -313.84 Book Value 03/31/22 - 2.34 12/31/21 - 3.38 09/30/21 - 4.19 Inventory Turnover 03/31/22 - 0.69 12/31/21 - 1.05 09/30/21 - 1.56 Debt-to-Equity 03/31/22 - 0.76 12/31/21 - 0.52 09/30/21 - 0.17 Debt-to-Capital 03/31/22 - 43.03 12/31/21 - 34.38 09/30/21 - 14.51

Powered by Zacks Investment Research ©